Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Company profile
Ticker
ENSC, ENSCW
Exchange
Website
CEO
Dr. D. Lynn Kirkpatrick Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Voya Financial • Alibaba Group Holding Limited • Carrier Global • XPeng • Rackspace Technology • NCR Atleos • IHS Markit • Match • IAC • Bumble ...
Former names
Yandex N.V.
SEC CIK
Corporate docs
Subsidiaries
Covistat, Inc. • EBI OpCo, Inc. • EBI Operating, Inc. ...
ENSC stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
18 Oct 24
DEFA14A
Additional proxy soliciting materials
18 Oct 24
EFFECT
Notice of effectiveness
18 Oct 24
DEF 14A
Definitive proxy
17 Oct 24
ARS
2023 FY
Annual report to shareholders
17 Oct 24
EFFECT
Notice of effectiveness
16 Oct 24
S-3
Shelf registration
9 Oct 24
POS AM
Prospectus update (post-effective amendment)
9 Oct 24
PRE 14A
Preliminary proxy
7 Oct 24
D
$5.06 mm in options / securities to be acquired, sold $5.06 mm, 4 investors
12 Sep 24
Transcripts
Latest ownership filings
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13D/A
GOWER BOB G
18 Jul 23
4
BOB G GOWER
6 Mar 23
4
BOB G GOWER
2 Mar 23
SC 13G/A
HG Vora Capital Management, LLC
14 Feb 23
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13G
Lincoln Park Capital Fund, LLC
7 Feb 23
4
BOB G GOWER
1 Feb 23
SC 13G
CVI Investments, Inc.
16 Dec 22
SC 13D/A
Silvers Daniel B.
7 Jul 22
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.04 mm | 1.04 mm | 1.04 mm | 1.04 mm | 1.04 mm | 1.04 mm |
Cash burn (monthly) | 787.04 k | 232.19 k | 651.81 k | 805.12 k | 769.96 k | 815.23 k |
Cash used (since last report) | 2.96 mm | 871.88 k | 2.45 mm | 3.02 mm | 2.89 mm | 3.06 mm |
Cash remaining | -1.91 mm | 171.35 k | -1.40 mm | -1.98 mm | -1.85 mm | -2.02 mm |
Runway (months of cash) | -2.4 | 0.7 | -2.2 | -2.5 | -2.4 | -2.5 |
Institutional ownership, Q2 2024
47.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 54.26 mm |
Total shares | 6.65 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Silvers Daniel B. | 2.88 mm | $2.50 mm |
Hydra LAC | 1.87 mm | $27.07 mm |
Lincoln Park Capital Fund | 1.50 mm | $1.17 mm |
CVI Investments | 336.87 k | $0.00 |
Geode Capital Management | 46.10 k | $23.33 mm |
Virtu Financial | 11.34 k | $6.00 k |
Main Street | 370.00 | $185.00 k |
Proequities | 0.00 | $0.00 |
News
Dow Falls Over 150 Points; General Motors Tops Q3 Views
22 Oct 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
22 Oct 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
22 Oct 24
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
22 Oct 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
30 Sep 24
Press releases
Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit
8 Oct 24
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
2 Oct 24
Ensysce Biosciences Receives Notice from Nasdaq
27 Sep 24
Ensysce Biosciences Presenting at Upcoming Meetings
24 Sep 24
Ensysce Biosciences Submits Phase 3 Protocol to the FDA
19 Sep 24